Population-Wide Screening for Chronic Kidney Disease
Authors: Marika M. Cusick, Rebecca L. Tisdale, Glenn M. Chertow, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert
Journal: Annals of Internal Medicine (2024)

LettersJanuary 2024Population-Wide Screening for Chronic Kidney DiseaseMarika M. Cusick, MS, Rebecca L. Tisdale, MD, MPA, Glenn M. Chertow, MD, MPH, Douglas K. Owens, MD, MS, Jeremy D. Goldhaber-Fiebert, PhDMarika M. Cusick, MSDepartment of Health Policy, Stanford School of Medicine, and Stanford Health Policy, Freeman Spogli Institute for International Studies, Stanford University, Stanford, CaliforniaSearch for more papers by this author, Rebecca L. Tisdale, MD, MPAVA Palo Alto Health Care System, Center for Innovation to Implementation, Menlo Park, CaliforniaSearch for more papers by this author, Glenn M. Chertow, MD, MPHStanford Health Policy, Freeman Spogli Institute for International Studies, and Department of Health Policy, Department of Epidemiology and Population Health, and Division of Nephrology, Department of Medicine, Stanford School of Medicine, Stanford, CaliforniaSearch for more papers by this author, Douglas K. Owens, MD, MSDepartment of Health Policy, Stanford School of Medicine, and Stanford Health Policy, Freeman Spogli Institute for International Studies, Stanford University, Stanford, CaliforniaSearch for more papers by this author, Jeremy D. Goldhaber-Fiebert, PhDDepartment of Health Policy, Stanford School of Medicine, and Stanford Health Policy, Freeman Spogli Institute for International Studies, Stanford University, Stanford, CaliforniaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L23-0370 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE: We appreciate the comments by Dr. van Mil and colleagues, who are leading experts in nephrology research. We agree that the cost-effectiveness of general population-wide screening for albuminuria could be even more favorable given anticipated decreases in the cost of SGLT2 inhibitors related to patent expirations and lower costs of albuminuria screening tools, including the innovative options proposed by Dr. van Mil and colleagues (1).We conducted a sensitivity analysis wherein we lowered the cost of the urine albumin–creatinine ratio test from $49 to $5 and the primary care provider visit from $200 to $10 (assuming a brief ...References1. van Mil D, Kieneker LM, Evers-Roeten B, et al. Protocol for a randomized study assessing the feasibility of home-based albuminuria screening among the general population: the THOMAS study. PLoS One. 2022;17:e0279321. [PMID: 36548281] doi:10.1371/journal.pone.0279321 CrossrefMedlineGoogle Scholar2. Jalal H, Dowd B, Sainfort F, et al. Linear regression metamodeling as a tool to summarize and present simulation model results. Med Decis Making. 2013;33:880-90. [PMID: 23811758] doi:10.1177/0272989X13492014 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Marika M. Cusick, MS; Rebecca L. Tisdale, MD, MPA; Glenn M. Chertow, MD, MPH; Douglas K. Owens, MD, MS; Jeremy D. Goldhaber-Fiebert, PhDAffiliations: Department of Health Policy, Stanford School of Medicine, and Stanford Health Policy, Freeman Spogli Institute for International Studies, Stanford University, Stanford, CaliforniaVA Palo Alto Health Care System, Center for Innovation to Implementation, Menlo Park, CaliforniaStanford Health Policy, Freeman Spogli Institute for International Studies, and Department of Health Policy, Department of Epidemiology and Population Health, and Division of Nephrology, Department of Medicine, Stanford School of Medicine, Stanford, CaliforniaDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L23-0370. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPopulation-Wide Screening for Chronic Kidney Disease Marika M. Cusick , Rebecca L. Tisdale , Glenn M. Chertow , Douglas K. Owens , and Jeremy D. Goldhaber-Fiebert Population-Wide Screening for Chronic Kidney Disease Dominique van Mil , Hiddo L. Heerspink , Ron T. Gansevoort Metrics Current Issue January 2024Volume 177, Issue 1 Keywords ACE inhibitor therapy Age groups Angiotensin converting enzyme Estimated glomerular filtration rate Health screening Mortality Quality adjusted life years Quality of life ePublished: 16 January 2024 Issue Published: January 2024 Copyright & PermissionsCopyright © 2024 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...